Samsung C&T's ownership structure for the common stock as of Dec 31, 2024 is as follows;
- Controlling shareholder and related parties 35%, treasury stock 9%
- Domestic institutions 12%, foreigners 26%, domestic individuals and others 18%
For further information, please refer to [IR > Stock Information > Ownership Structure].

As of Dec 31, 2024, total number of stocks issued by Samsung C&T is 179,251,697 shares. Of the total volume, 177,784,107 shares are common stocks and 1,467,590 shares are preferred stocks.
※ For your information, the date of Samsung C&T's stock listion after the merger is September 15,2015.

Stock related information can be found at [IR > Stock Information > Stock Charts] and [IR > Stock Information > Valuation]and .

Samsung C&T wholly owns Samsung Welstory - a food & beverage subsidiary- and approximately 43% of Samsung Biologics share.
Samsung Biologics has Samsung BioEpis(biosimilar drugs R&D company) as a wholly owned subsidiary.

Generally, dividends are paid to the shareholders within 1 month after the BOD approves financial statements in the annual general meeting of shareholders, which includes total dividend amount, as stipulated in the relevant regulations to the registered shareholders as of end of December.
At the annual general meeting of shareholders on March 14, 2025, annual financial statements containing the total dividend amount (Common stock KRW 2,600 per share, preferred stock KRW 2,650 per share) was approved.
ㆍPeriod: July 24 2015 ~ October 8 2015
ㆍRepurchased stocks: 2.5 million shares, KRW 409 billion

Samsung C&T's common and preferred stock is listed on Korea Stock Exchange(KRX) under the ticker symbol of 028260, 02826K respectively.